Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Midodrine hydrochloride
Brancaster Pharma Ltd
C01CA17
Midodrine hydrochloride
10mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02070200; GTIN: 05060432470234
symptoms such as pain or cramps in the stomach after eating, or pain or cramps in the legs while walking. • suffer from a disease of the prostate, as you may find passing urine is difficult when taking this medicine. You should have your kidney function and blood pressure checked by your doctor before you start using this medicine. During treatment with this medicine, your blood pressure will be checked from time to time, and if necessary your dose adjusted. It is important that you immediately report symptoms related to high blood pressure, such as chest pain, palpitations, shortness of breath, headache and blurred vision. Your doctor will then decide whether to adjust dosage or discontinue your treatment with Bramox tablets. If any of the warnings apply to you, or have in the past, talk to your doctor. CHILDREN AND ADOLESCENTS Do not give this medicine to children and adolescents under the age 18 because the safety and efficacy of Bramox tablets in this age group have not been established. OTHER MEDICINES AND BRAMOX TABLETS Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. IN PARTICULAR, TELL YOUR DOCTOR OR PHARMACIST IF YOU ARE TAKING ANY OF THE FOLLOWING: • Concomitant use with these medicines may cause a large increase in blood pressure: • Reserpine and guanethidine (medicines used to reduce high blood pressure) • Antihistamines (used to treat allergies) • Hormones for the thyroid (used when the thyroid is not working properly) • Tricyclic antidepressants and MAO-inhibitors (both used to treat depression) • Other vasoconstrictors (medicines that narrow blood vessels), or sympathomimetic agents (medicines that have a stimulating effect on certain parts of the nervous system). • Prazosin and phentolamine (medicines used to treat heart disease) because the effect of this medicine is blocked by these drugs. • Digitalis preparations (medicines used to treat heart disease) because concomitant use with this medicine may lead to cardiac dysfunc Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bramox 10 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg of midodrine hydrochloride. Excipients with known effect: Each tablet contains 0.1 mg Brilliant blue FCF aluminium lake (E133). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Blue, round tablet of diameter 7 mm. Debossed “APO” on one side with “MID” debossed above the score line and “10” debossed below the score line on the other side. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Bramox 10 mg tablets are indicated in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Initial dose: 2.5 mg three times a day (Bramox 2.5 mg tablets are also available). Depending on the results of supine and standing blood pressure recordings, this dose may be increased weekly up to a dose of 10 mg three times a day. This is the usual maintenance dosage. A careful evaluation of the response to treatment and of the overall balance of the expected benefits and risks needs to be undertaken before any dose increase and advice to continue therapy for long periods. The last daily dose should be taken at least 4 hours before bedtime in order to prevent supine hypertension (see also section 4.4). Bramox 10 mg tablets may be taken with food (see section 5.2). _Paediatric population _ The safety and efficacy of midodrine in children have not been established. No data are available. _Elderly population _ There is limited data on dosing in the elderly and there are no specific studies which have focused on a possible dose reduction in the elderly population. Cautious dose titration is recommended. _Patients with renal impairment _ There are no specific studies that Read the complete document